http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Arrowhead Pharmaceuticals (ARWR) Receives FDA Breakthrough Therapy Designation for Plozasiran
-
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
-
Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals Inc. (ARWR) to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals to Present New Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals Inc. (ARWR) to Advance ARO-INHBE and ARO-ALK7 Into Clinical Studies
-
Arrowhead Pharmaceuticals to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, Into Clinical Studies
-
Arrowhead Pharmaceuticals (ARWR) Announces $500 Million Strategic Financing Facility with Sixth Street
-
Arrowhead Pharmaceuticals Reports Fiscal 2024 Third Quarter Results
-
Arrowhead Pharmaceuticals Announces $500 Million Strategic Financing Facility with Sixth Street
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Third Quarter Results
-
Arrowhead Pharmaceuticals (ARWR) to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
-
Arrowhead Pharmaceuticals to Advance RNAi-based Plozasiran into Phase 3 CAPITAN Cardiovascular Outcomes Trial
-
Arrowhead Pharmaceuticals Inc. (ARWR) Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
-
Arrowhead Pharmaceuticals Presents Preclinical Data on New RNAi-Based Obesity Program ARO-INHBE
-
Arrowhead Pharmaceuticals (ARWR) Reports Successful Results for Plozasiran from the Phase 3 PALISADE Study
-
Arrowhead Pharmaceuticals Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 PALISADE Study in Patients with Familial Chylomicronemia Syndrome
-
Arrowhead Pharmaceuticals to Participate in Upcoming June 2024 Conferences
-
Arrowhead Pharmaceuticals (ARWR) Presents New Phase 2 Data of Zodasiran
-
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Zodasiran in Patients with Mixed Hyperlipidemia
-
Arrowhead Pharmaceuticals (ARWR) Presents New Phase 2 Data of Plozasiran
-
Arrowhead Pharmaceuticals Presents New Phase 2 Data of Plozasiran in Patients with Mixed Hyperlipidemia
-
Arrowhead Pharmaceuticals (ARWR) Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
-
Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma
-
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
-
Arrowhead Pharmaceuticals (ARWR) Earns $50M Milestone from Royalty Pharma (RPRX)
-
Arrowhead Pharmaceuticals Earns $50 Million Milestone from Royalty Pharma
-
Arrowhead Pharmaceuticals to Participate in Upcoming May 2024 Conferences
-
Arrowhead Pharmaceuticals to Host 2024 Summer Series of R&D Webinars
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 Second Quarter Results
-
Arrowhead Pharmaceuticals Inc. (ARWR) Initiates Phase 1/2a Study of ARO-CFB
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease
-
Arrowhead Pharmaceuticals Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals Initiates Expanded Access Program for Plozasiran and Announces Upcoming Presentation of Clinical Data
-
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy
-
Arrowhead Pharmaceuticals to Participate in Upcoming March 2024 Conferences
-
Arrowhead Pharmaceuticals Reports Fiscal 2024 First Quarter Results
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2024 First Quarter Results
-
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
-
Arrowhead Pharmaceuticals Inc. (ARWR) Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB
-
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-CFB for Complement Mediated Kidney Disease
-
Arrowhead Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Arrowhead Pharmaceuticals Reports Fiscal 2023 Year End Results
-
Arrowhead Pharmaceuticals (ARWR) Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
-
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy
-
Arrowhead Pharmaceuticals to Participate in Piper Sandler 35th Annual Healthcare Conference
-
Arrowhead Pharmaceuticals to Webcast Fiscal 2023 Year End Results
-
Arrowhead Pharmaceuticals Inc. (ARWR) Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023
